Skandinaviska Enskilda Banken (SEB)
APLS

Skandinaviska Enskilda Banken (SEB)’s Apellis Pharmaceuticals APLS Stock Holding History

Skandinaviska Enskilda Banken (SEB)’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-25,581
Closed -$737K – 841
2024
Q3 		$737K Hold
25,581
– – ﹤0.01% 695
2024
Q2 		$982K Hold
25,581
– – ﹤0.01% 645
2024
Q1 		$1.5M Sell
25,581
-4,900
-16% -$312K 0.01% 619
2023
Q4 		$1.82M Buy
30,481
+4,900
+19% +$249K 0.01% 602
2023
Q3 		$972K Sell
25,581
-3,860
-13% -$170K 0.01% 680
2023
Q2 		$2.68M Hold
29,441
– – 0.02% 492
2023
Q1 		$1.94M Sell
29,441
-1,405
-5% -$81.1K 0.01% 558
2022
Q4 		$1.59M Sell
30,846
-6,208
-17% -$329K 0.01% 591
2022
Q3 		$2.53M Hold
37,054
– – 0.02% 482
2022
Q2 		$1.68M Hold
37,054
– – 0.01% 616
2022
Q1 		$1.88M Buy
+37,054
New +$1.64M 0.01% 639

Other funds holding APLS

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Skandinaviska Enskilda Banken (SEB)'s APLS Position: Q4 2024 in Review

Skandinaviska Enskilda Banken (SEB) sold out of Apellis Pharmaceuticals (APLS) in Q4 2024, closing a stake of 25,581 shares — an estimated $737K sold.

Skandinaviska Enskilda Banken (SEB) first reported a position in APLS in Q1 2022 and held it in 11 quarters. The position peaked at $2.68M in Q2 2023. 260 funds tracked by Wall St. Rank hold APLS as of Q4 2024.

  • Skandinaviska Enskilda Banken (SEB) reported no remaining Apellis Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Skandinaviska Enskilda Banken (SEB) sold 25,581 Apellis Pharmaceuticals shares in Q4 2024, an estimated $737K.
  • Skandinaviska Enskilda Banken (SEB) first reported a position in Apellis Pharmaceuticals in Q1 2022 and held it in 11 quarters.
  • Skandinaviska Enskilda Banken (SEB)'s Apellis Pharmaceuticals position peaked at $2.68M in Q2 2023.
  • 260 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q4 2024.

Based on Skandinaviska Enskilda Banken (SEB)'s 13F filing for Q4 2024, filed 10 Feb 2025.